Advertisement
Screener

Pyxis Oncology, Inc. (PYXS) Restricted Cash

2.8 / 5 stars · 68/120 Roast Me

Pyxis Oncology, Inc. Restricted Cash

Pyxis Oncology, Inc. (PYXS) had Restricted Cash of $1.47 million as of 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Balance Sheet › Assets

us-gaap:RestrictedCash · last filed 2026-08-13

  • 2026-06-30: Restricted Cash $1.47M.
  • 2026-03-31: Restricted Cash $1.47M.
  • 2025-12-31: Restricted Cash $1.47M.
  • 2025-09-30: Restricted Cash $1.47M.
Period endRestricted Cash
2026-06-30$1.47M
10-Q · filed 2026-08-13
2026-03-31$1.47M
10-Q · filed 2026-05-14
2025-12-31$1.47M
10-K · filed 2026-03-23
2025-09-30$1.47M
10-Q · filed 2025-11-03
2025-06-30$1.47M
10-Q · filed 2026-08-13
2025-03-31$1.47M
10-Q · filed 2026-05-14
2024-12-31$1.47M
10-K · filed 2026-03-23
2024-09-30$1.47M
10-Q · filed 2025-11-03
2024-06-30$1.47M
10-Q · filed 2025-08-14
2024-03-31$1.47M
10-Q · filed 2025-05-15
2023-12-31$1.47M
10-K · filed 2025-03-18
2023-09-30$1.47M
10-Q · filed 2024-11-12
2023-06-30$1.47M
10-Q · filed 2024-08-14
2023-03-31$1.47M
10-Q · filed 2024-05-14
2022-12-31$1.47M
10-K · filed 2024-03-21
2022-09-30$1.47M
10-Q · filed 2023-11-07
2022-06-30$1.47M
10-Q · filed 2023-08-11
2022-03-31$1.58M
10-Q · filed 2023-05-11
2021-12-31$1.58M
10-K · filed 2023-03-22
2021-09-30$109.00K
10-Q · filed 2022-11-01
2021-06-30$108.00K
10-Q · filed 2022-08-15
2021-03-31$109.00K
10-Q · filed 2022-05-13
2020-12-31$108.00K
10-K · filed 2022-03-29
2020-09-30$109.00K
10-Q · filed 2021-11-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55